PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.27
0.10 (4.61%)
▲
5d:
+10.19%
30d:
+8.1%
90d:
+9.66%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PLX is 8.6% above its trading range ($2.09). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PLX is 8.6% above its trading range ($2.09). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.27, which is considered extended relative to its 30-day fair value range of $1.95 to $2.09. From a valuation perspective, the stock is trading at a premium (Forward PE: 43.4) compared to its historical average (27.6). At these levels, the market is pricing in 16.2% annual earnings growth.
Technical Outlook: Technically, PLX is in a strong downtrend. The price is approaching resistance at $2.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: PLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+406.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PLX is in a strong downtrend. The price is approaching resistance at $2.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: PLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+406.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.95 -
$2.09
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range (+8.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 406.9% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 16.2% growth with 233.7% revenue growth
- CAUTION: Extended 8.6% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.95 -
$2.09
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.19
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.40
Wall Street Target
$11.00
(+406.9%)
Revenue Growth (YoY)
233.7%
Earnings Growth (YoY)
-1.0%
Profit Margin
20.1%
Valuation Premium vs History
+16.2% premium
PE vs Historical
43.4 vs 27.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.2%
(market-implied from PE analysis)
1-Year Target
$2.52
(+16%)
2-Year Target
$2.93
(+35%)
3-Year Target
$3.40
(+57%)
3-Yr Target (if PE normalizes)
(PE: 43→28)
PE COMPRESSION
$2.17
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.4, Growth: -74.4%)
$1.58
(+-27%)
Base:
(SPY PE: 21.8, Growth: -74.4%)
$0.79
(-63%)
Bear:
(PE: 18.5, Growth: -74.4%)
$0.67
(-69%)
📈
Valuation based on Current Earnings
Trailing PE: 11.37 | Current EPS (TTM): $0.19
Bull Case
$1.19
(-45%)
Analyst growth -50.0%, PE expands to 12.5
Base Case
$1.08
(-50%)
Market implied -50.0%, PE stable at 11.4
Bear Case
$1.47
(-32%)
Severe decline -20.0%, PE contracts to 9.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 1:59 PM ET
Data refreshes hourly during market hours. Next update: 2:59 PM
Data refreshes hourly during market hours. Next update: 2:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
